A Phase 1/2 Study Investigating The Safety And Efficacy Of Autologous Tac T Cells In Subjects With Unresectable, Locally Advanced Or Metastatic Claudin 18.2+ Solid Tumors
Posted Date: Apr 25, 2024
- Investigator: Davendra Sohal
- Specialties:
- Type of Study: Drug
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor.
Criteria:
Null
Keywords:
Cell Therapy
For More Information:
Kayla Webb
NULL
cancer@uchealth.com